ReviewMolecular biomedicine2026
Recent advances in antituberculosis drugs and therapeutics: from mechanistic breakthroughs to clinical translation.
Review in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis, reclaimed its status as the deadliest single-pathogen infectious disease globally in 2023, accounting for 10.8 million new cases and 1.25 million deaths in 2023. The escalating crisis of drug-resistant TB, suboptimal BCG vaccine efficacy in adults, and persistent treatment gaps for vulnerable populations collectively drive an urgent shift toward mechanism-driven, precision-oriented therapeutic strategies.This review presents a critically integrated appraisal of anti-TB research advances spanning 2020 to 2025, drawing on structural biology, multi-omics, and real-world clinical evidence. It distinguishes itself from conventional descriptive literature compilations through systematic cross-population efficacy comparisons, in-depth dissection of translational bottlenecks, and explicit maturity stratification of emerging biotherapies. We synthesize progress across six interconnected domains: mechanistic insights into drug targets and spatiotemporal resistance evolution, novel short-course therapeutic regimens, precision medicine strategies, host-directed therapies, targeted delivery systems for extrapulmonary TB, and next-generation vaccine development. Three transformative breakthroughs are particularly highlighted: structural biology-guided rational drug design, spatial immune profiling of tuberculous granulomas, and AI-assisted diagnostic pipelines.We conclude by delineating priority research directions aligned with the WHO End TB Strategy, providing a translational roadmap to advance global TB elimination efforts. This rigorous, multi-dimensional synthesis offers an authoritative reference for advancing basic and translational anti-TB research and informing global public health strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.